Research Scope

The study for Global Overactive Bladder Treatment Market will provide market size, estimates and forecast based on the following years: 

Historic data: 2015  Base Year Estimate: 2016  Forecast: 2017 to 2025

The report has been categorized in two distinctive sections, where the first category titled as Market Overview provides a holistic view of the market, key trends, drivers, challenges/restraints or opportunities with their current and expected impact on the overall industry sales. 

Our analyst implement several qualitative tools such as Ansoff’s Matrix, PESTEL analysis, Porter’s five force analysis among other to interpret and represent key industry findings. 

The second section of the study provides market size, estimates and forecast for key market segments and regional market. The final part of the report highlights key manufacturers/vendors operating in the associated market.  

1. Introduction

1.1. Market Definition

1.2. Market Scope

2. Research Methodology

2.1. Primary Research

2.2. Secondary Sources

2.3. Assumptions & Exclusions

3. Market Overview

3.1. Research Report Segmentation & Scope

3.2. Key Market Trend Analysis

3.2.1. Market Drivers

3.2.2. Market Restraint/Challenges

3.2.3. Market Opportunities

3.3. Porter’s Five Forces Analysis

3.4. Potential Venture Avenues

3.5. Market Share Analysis, 2016 

3.6. Market Overview

4. Type Overview

4.1. Introduction

4.2. Market Size & Forecast, 2015 to 2025

4.2.1. Idiopathic bladder overactivity 

4.2.2. Neurogenic bladder overactivity

 (Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

5. Treatment Overview

5.1. Introduction

5.2. Market Size & Forecast, 2015 to 2025

5.2.1. Anticholenergic Drugs

5.2.2. Beta-3 Adrenergic Drug

5.2.3. Antidepressants Drugs

5.2.4. Hormones

5.2.5. BOTOX

5.2.6. Others

(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

6. Route of Administration

6.1. Introduction

6.2. Market Size & Forecast, 2015 to 2025

6.2.1. Oral

6.2.2. Topical 

6.2.3. Rectal

6.2.4. Parenteral

6.2.5. Others

(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

7. End User

7.1.1. Clinics and Hospitals

7.1.2. Ambulatory Care

7.1.3. Others

(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

8. Regional Overview

8.1. Introduction

8.2. Market Size & Forecast, 2015 to 2025

8.2.1. North America

8.2.1.1. U.S.

8.2.1.2. Canada

8.2.1.3. Mexico 

8.2.2. Europe

8.2.2.1. UK

8.2.2.2. Germany

8.2.2.3. France

8.2.2.4. Italy 

8.2.2.5. Spain

8.2.2.6. Rest of Europe

8.2.3. Asia-Pacific

8.2.3.1. China

8.2.3.2. India

8.2.3.3. Japan

8.2.3.4. South Korea

8.2.3.5. Rest of Asia-Pacific

8.2.4. LAMEA

8.2.4.1. Brazil

8.2.4.2. UAE

8.2.4.3. South Africa

8.2.4.4. Rest of LAMEA

(Note: The segments mentioned above are tentative in nature and are subject to change as the research progresses)

9. Manufacturer/ Vendor Profile

9.1. The following attributes will be considered while profiling key manufacturers in this industry: 

9.1.1. Company Overview

9.1.2. Financial Synopsis

9.1.3. Recent Developments

9.1.4. R&D Investments (if any)

9.1.5. Strategy Overview (Analyst Perspective)

9.1.6. Product Portfolio

9.2. Companies Profiled

9.2.1. Astellas Pharma, Inc.  

9.2.2. Pfizer, Inc.  

9.2.3. Allergan, Plc.  

9.2.4. Teva Pharmaceutical Industries Limited 

9.2.5.  Mylan N.V. 

9.2.6. Medtronic plc 

9.2.7. Endo International plc. 

9.2.8. Sanofi 

9.2.9. Hisamitsu Pharmaceutical Co., Inc. 

9.2.10. Aurobindo Pharma Limited  

(Note: The companies mentioned above are tentative in nature, and profiles of other market players not listed here can be included on request.)